SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-247767
Filing Date
2022-09-20
Accepted
2022-09-20 17:03:54
Documents
14
Period of Report
2022-09-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d399674d8k.htm   iXBRL 8-K 24628
2 EX-99.1 d399674dex991.htm EX-99.1 36555
6 GRAPHIC g399674capture.jpg GRAPHIC 11292
  Complete submission text file 0001193125-22-247767.txt   205747

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stsa-20220920.xsd EX-101.SCH 2864
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20220920_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20220920_pre.xml EX-101.PRE 11713
8 EXTRACTED XBRL INSTANCE DOCUMENT d399674d8k_htm.xml XML 3465
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39041 | Film No.: 221254381
SIC: 2834 Pharmaceutical Preparations